| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Tuesday’s Close |
|---|---|---|---|---|---|
| NVS | Novartis AG | $85.13 | $197.65B | Uptrend |
Amgen (AMGN) Continues to Reward Shareholders, Ups Dividend
http://www.zacks.com/stock/news/342114/amgen-amgn-continues-to-reward-shareholders-ups-dividend?cid=CS-ZC-FT-342114
Dec 10, 2018 - Amgen (AMGN) hikes its quarterly dividend by 10%.
0
ADMP And Sandoz Announce Plans For SYMJEPI Launch
https://seekingalpha.com/article/4227049-admp-sandoz-announce-plans-symjepi-launch?source=feed_sector_healthcare
Dec 07, 2018 - Adamis and Sandoz announce an expected SYMJEPI launch in Q1 2019.Sandoz announces SYMJEPI’s WAC of $250 vs. $300 for Mylan’s and Teva’s generic EpiPen.Adamis has completed manufacturing, and is shippi
0
Conatus May Still Have A Path Forward After Latest Phase 2b Data
https://seekingalpha.com/article/4226987-conatus-may-still-path-forward-latest-phase-2b-data?source=feed_sector_healthcare
Dec 07, 2018 - Conatus Pharmaceuticals didn't meet primary endpoint for phase 2b ENCORE-PH study, but a subgroup analysis of compensated cirrhosis patients had a clinically meaningful effect when taking emricasan.Th
0
Novartis Presents Additional Data on Breast Cancer Candidate
http://www.zacks.com/stock/news/341919/novartis-presents-additional-data-on-breast-cancer-candidate?cid=CS-ZC-FT-341919
Dec 07, 2018 - Novartis (NVS) presents supplementary data from phase III study on BYL719 in combination with Faslodex for the treatment of advanced breast cancer. The study scripts success in PFS.
0
Pharma Stock Roundup: Glaxo's TESARO Buyout & Horlicks Sale, ASH Cancer Data Updates
http://www.zacks.com/stock/news/341786/pharma-stock-roundup-glaxos-tesaro-buyout-horlicks-sale-ash-cancer-data-updates?cid=CS-ZC-FT-341786
Dec 07, 2018 - Glaxo (GSK) to buy TESARO and divest Horlicks brand to Unilever. ASH cancer presentations grab headilines.
0
Celgene Doesn't Want To Be Left Out, Posts Promising JCAR017 Data
https://seekingalpha.com/article/4226884-celgene-want-left-posts-promising-jcar017-data?source=feed_sector_healthcare
Dec 06, 2018 - Celgene announces positive preliminary data from its study treating patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) using JCAR017.A key risk i
0
THW: Global Healthcare Fund With 10%+ Yield
https://seekingalpha.com/article/4226785-thw-global-healthcare-fund-10-percent-yield?source=feed_tag_etf_portfolio_strategy
Dec 06, 2018 - THW is a Tekla healthcare fund much like THQ, but with an emphasis on holding global securities.THW currently has a quite attractive 10.55% yield.This fund is also showing a discount of 8.29%, but tha
0
Eye Drug Continues to Drive Regeneron's Growth
http://www.gurufocus.com/news/780907/eye-drug-continues-to-drive-regenerons-growth-
Dec 04, 2018 - Eye Drug Continues to Drive Regeneron's Growth, Stocks: REGN,NVS,RHHBY,XTER:BAYN,IBB,RGNY,APLS,OPHT,AGN, release date:Dec 04, 2018
0
Incyte (INCY) Announces Positive Data on Jakafi for GVHD
http://www.zacks.com/stock/news/341138/incyte-incy-announces-positive-data-on-jakafi-for-gvhd?cid=CS-ZC-FT-341138
Dec 04, 2018 - Incyte (INCY) announces positive data on lead drug Jakafi at the ASH meet for the indication of acute GVHD.
0
Gilead (GILD) Announces Data on CAR T Therapy Candidate
http://www.zacks.com/stock/news/341121/gilead-gild-announces-data-on-car-t-therapy-candidate?cid=CS-ZC-FT-341121
Dec 04, 2018 - Gilead (GILD) announces data on chimeric antigen receptor T (CAR T) cell therapy candidate at the ASH for the treatment of patients with relapsed or refractory acute lymphoblastic leukemia.
0
Page 1>
Related Companies
| Name | Exchange | Price | Mkt Cap | |
| MRK | Merck & Company, Inc. | NYSE | $70.42 | $187.28B |
| ABBV | AbbVie Inc. | NYSE | $95.37 | $144.42B |
| PFE | Pfizer, Inc. | NYSE | $43.01 | $252.13B |
| ABT | Abbott Laboratories | NYSE | $67.67 | $118.71B |
| NVO | Novo Nordisk A/S | NYSE | $47.64 | $114.84B |
NVS - Nasdaq
http://www.nasdaq.com/symbol/nvs
Quote information directly from the exchange
SEC filings
Comparison
Ownership
Insiders
Institutions
Revenue/EPS
Competitors
Guru
Report
Analysts
Pre-market
Quote
Consultant
After hours
Transcripts
NVS - Google Finance
https://www.google.com/finance?q=NVS
Industry related info and international coverage
Summary
News
NVS - Bloomberg
http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=NVS
Original news and commentary from Bloomberg
Charts
Financials with pensions
Snapshot
Earnings
Transactions
People
Options